The proposal is to complete the chemical development, efficacy and safety evaluation of an ant malarial articulate, which has not yet been registered for use in the EU or US. The intended beneficiary is a patient living in or travelling to a malaria endemic country. The drug is being developed to provide therapeutic cover for patients with severe disease, who can no longer take drugs by mouth, and who cannot access inject able treatment, until they can reach facilities where definitive therapy can be provided. Costs cover completion of the chemical development, proof of bio equivalence, and clinical trials to establish efficacy of the GMP product and its safety.
Funding SchemeDEM - Demonstration contracts